Why the study?
It remains unclear which method best localizes ganglionated plexi, how many should be targeted, and the long-term consequences of these therapies.
Does ganglionated plexus ablation improve outcomes in patients with atrial fibrillation?
Does ganglionated plexus ablation improve outcomes in patients with atrial fibrillation?
This review discusses the available evidence on the clinical impact of ganglionated plexus ablation for treating atrial fibrillation, highlighting uncertainties in localization methods and long-term consequences.
GP ablation should not yet change PVI-based practice; leaves open localization methods, complete denervation, and reinnervation prevention.
The role of the autonomic nervous system (ANS) in the onset and maintenance of atrial fibrillation (AF) may be related to autonomic imbalance. The ANS may cause specific cellular electrophysiological phenomena, such as, shortening of the atrial effective refractory periods (ERPs) and ectopy based on firing activity in pulmonary vein myocytes. High frequency stimulation of atrial ganglionated plexi (GPs) may cause an increase in ERP dispersion and induce AF. Autonomic modification strategies by targeting GPs with catheter ablation have emerged as new targets. Various strategies have been used to detect location of GPs.However, it is still not clear which is the best method to localize GPs, how many GPs should be targeted, and what are the long-term consequences of these therapies. In this review, we discuss available evidence on the clinical impact of GP ablation to treat AF.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: